1. Home
  2. GLBS vs RNTX Comparison

GLBS vs RNTX Comparison

Compare GLBS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globus Maritime Limited

GLBS

Globus Maritime Limited

HOLD

Current Price

$2.15

Market Cap

43.8M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.02

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLBS
RNTX
Founded
2006
2001
Country
Greece
United States
Employees
N/A
10
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.8M
47.7M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
GLBS
RNTX
Price
$2.15
$1.02
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$3.00
$10.00
AVG Volume (30 Days)
59.2K
841.5K
Earning Date
06-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.06
N/A
Revenue Next Year
$20.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.95
52 Week High
$2.44
$2.18

Technical Indicators

Market Signals
Indicator
GLBS
RNTX
Relative Strength Index (RSI) 58.00 39.26
Support Level $1.83 N/A
Resistance Level $2.18 $1.33
Average True Range (ATR) 0.11 0.08
MACD 0.01 0.01
Stochastic Oscillator 75.00 24.94

Price Performance

Historical Comparison
GLBS
RNTX

About GLBS Globus Maritime Limited

Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: